Understanding how genetic and immune factors affect bladder cancer treatment with sacituzumab and radiation.
Official title: Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10896483 · Data updated 2026-11-12
This study is looking at how your genes and immune system affect how well bladder cancer patients respond to a special treatment that combines a drug called sacituzumab with radiation, so we can find out why some people do better than others and help create better treatments for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 14, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $209,500 |
| NIH project number | 5U54CA274513-03 |
| Project ID | NIH-10896483 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with muscle invasive bladder cancer who are undergoing treatment with sacituzumab and radiation.
✕Less likely to help
Patients with non-muscle invasive bladder cancer or those who are not receiving sacituzumab or radiation therapy may not benefit from this research.
What this research studies
This research investigates the genetic and immune mechanisms that influence how bladder cancer patients respond to a combination of sacituzumab, an antibody-drug conjugate, and radiation therapy. The study aims to identify why some patients benefit from this treatment while others do not, focusing on the molecular and environmental factors involved. By analyzing patient samples and treatment outcomes, the researchers hope to develop more effective therapies that improve survival and bladder preservation rates for those with muscle invasive bladder cancer.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for bladder cancer patients, improving their chances of survival and quality of life.
How similar studies have gone: Previous research has shown promise in using antibody-drug conjugates in combination with radiation therapy for various cancers, suggesting potential for success in this approach for bladder cancer.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Chan, Timothy an-Thy — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chan, Timothy an-Thy
Related research
Other NIH-funded projects on the same topics.
-
Genetic and Immune Factors in Squaring the Room: Sacituzumab plus Radiation for Bladder Cancer
A study aims to understand why combining sacituzumab with radiation helps some bladder cancer patients more than others, with the goal of making bladder-sparing therapy more effective.
-
Targeted Internal Radiation and Immune Therapy for Non-Muscle-Invasive Bladder Cancer
Aims to help people with early bladder cancer that doesn’t respond to current therapy by using a novel intravesical treatment that combines targeted radiation, immune checkpoint inhibitors, and oncolytic virus to trigger a strong anti-cancer response.
-
How genetics and the immune system affect sacituzumab plus radiation for bladder cancer
This work looks at whether adding the antibody-drug sacituzumab to radiation helps people with muscle-invasive bladder cancer and which genetic or immune factors change that response.
-
Protecting small blood vessels from radiation by boosting mitochondrial health
It aims to prevent radiation-related damage to tiny blood vessels and reduce later thinking and memory problems in people who get radiation therapy by protecting cell mitochondria.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.